Xiaolan Fu

Time to benefit of perioperative immunotherapy among patients with resectable non-small-cell lung cancer

Abstract Background The optimal duration of perioperative immunotherapy for resectable non–small-cell lung cancer (NSCLC) remains undefined, and conventional efficacy measures provide limited insight into the temporal pattern of benefit emergence, for which time-to-benefit (TTB)...